Applied Integrin Sciences, Inc. Revolutionizing Cancer Therapeutics

1. Applied Integrin Sciences, Inc.Revolutionizing Cancer Therapeutics Company Introduction Douglas C. Lane, CEO Office: 310-443-4254 Direct: 310-457-0982 Mobile: 310-490-0567 Email: dclane@integrins.com Web: www.integrins.com

2. Imagine a world where we no longer have to fear cancer . . . Applied Integrin Sciences, Inc.

3. Introduction Applied Integrin Sciences is a biopharmaceutical company committed to discover, develop, and commercialize novel protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life. The Company’s Founding Scientists at the University of Southern California’s Keck School of Medicine and the Norris Comprehensive Cancer Center discovered and developed a drug discovery platform for producing novel, first-in-class protein therapeutics. This new class of cancer drug proteins induce a unique cellular-modulating characteristic that stops targeted cells from physically moving, preventing new blood vessels formation for tumors and preventing metastatic cells from migrating to new distant sites and seeding new tumors. Vicrostatin, the Company’s lead candidate, demonstrated strong anti-cancer therapeutic effects in six aggressive metastatic cancers through anti-angiogenic activity and anti-metastatic effects – independent of the type of solid tumor or cancer tissue origin - with no observable toxic effects. Applied Integrin Sciences, Inc.

4. Unmet Medical Needs • 12 Million New Cases of Cancer In 2011 • $96 Billion Spent On Oncology Therapeutics • Leading Cancer Drug – Avastin - $8 Bn • 8 Million Cancer Deaths in 2011 • 92% of Cancer Deaths Due To Metastasis • Annual Global Investment To Treat/Stop Metastasis • 5% of Global Rx R&D (Pharma, Biotech, Public, Private) Applied Integrin Sciences, Inc.

5. New Class Of Targeted Cancer Rx • rDisintegrin Peptides (Integrin Receptor Agonists) • Integrins Overexpressed and Dysregulated In: • Tumor-initiated Angiogenic Vasculature • Primary Tumors • Metastatic Foci • Therapeutic Modality: • Anti-angiogenic • Anti-metastatic Effects • Primary Mechanism of Action: • Collapse Cellular Motility Applied Integrin Sciences, Inc.

6. Cancer Therapeutic Effects Integrins Mediate Cellular Motility Motility Required for Angiogenesis Vascular Endothelial Cell Migration Motility Required for Metastasis Malignant Cell Migration Tissue Adhesion and Invasion Therapeutic Effect: Single Mechanism of Action: Impede Cellular Motility Two Therapeutic Effects: Angiogenesis & Metastasis Applied Integrin Sciences, Inc.

7. Tumor-initiated Angiogenesis Angiogenesis Produces Vascularized Tumor Fully Enabled To Complete Lethal Progression The Angiogenesis Foundation; http://www.angio.org Applied Integrin Sciences, Inc.

8. Therapeutic Significance • 21 Angiogenic Factors • Inhibit 1: $21 Bn Market • Avastin: VEGF Inhibitor • Inhibit 5 Angiogenic Processes • + Anti-metastatic Effects • $21+ Bn Market • Lead Candidate – VCN • 2nd Candidate – AMD01 The Angiogenesis Foundation; http://www.angio.org Applied Integrin Sciences, Inc.

9. Therapeutic Profile • Retain/Improve Anti-Angiogenic Rx Effects • Entirely Different MOA; Effective; Independent IP; FTO • VCN Targeted Agonist Effects To Produce: • Improved Safety: Reduce Toxicity and Side Effects • Improved Survival:From Sustained Therapeutic Effects • Extended Indications: Effective In Most Solid Tumors • Concurrent Antagonist Effects From Binding Characteristics • Same Molecule Produces Anti-Metastatic Effects • Compelling Aggregate Target Product Profile Applied Integrin Sciences, Inc.

10. Lead Candidate: Vicrostatin (VCN) Primary MOA: Impedes Cellular Motility Secondary MOA: Integrin Antagonist Activity Independent of Solid Tumor Type or Origin No Observed Toxicity • In Vivo and In Vitro Efficacy Demonstrated: • Breast • Prostate (Primary) • Prostate (Bone) • Ovarian • Melanoma • Malignant Glioblastoma Applied Integrin Sciences, Inc.

11. In Vivo Therapeutic Efficacy • Triple Negative Breast Cancer Tumor Model • MDA-MB-231 Xenografts • Reduced Tumor Progression • Increased Survival • Comparisons: • Docetaxel • Avastin • 1st Candidate: Vicrostatin (VCN) • 2nd Candidate: ADM01 (ADAM-Derived Disintegrin) Applied Integrin Sciences, Inc.

12. VCN Reduces Tumor Growth Breast Cancer MDA-MB-231 Xenografts Control VCN1 Avastin VCN2 1 2 3 4 5 6 7 6 9 Weeks Since Tumor Implantation Applied Integrin Sciences, Inc.

13. VCN Increases Survival Breast Cancer MDA-MB-231 Xenografts Control VCN1 Avastin VCN2 Time (Days) Applied Integrin Sciences, Inc.

14. ADM01 Reduces Tumor Growth Breast Cancer MDA-MB-231 Xenografts Control DTX Avastin ADM01 1 2 3 4 5 6 7 6 9 Weeks Since Tumor Implantation Applied Integrin Sciences, Inc.

15. ADM01 Increases Survival Breast Cancer MDA-MB-231 Xenografts Control DTX Avastin ADM01 Time (Days) Applied Integrin Sciences, Inc.

16. Market Opportunity Example: Avastin Worldwide Sales & Industry Comparison1 2017 Peak Avastin Sales > $8 Billion 9% of $96 Billion Oncology Market 2% of Total Pharma Market USD $ Billions 1Source: Goldman, Sachs & Co. 03-Nov-2008; Genentech Revenue Projections; Genentech Inc Form: SC 14D9/A SEC Filing 03/23/2009 Applied Integrin Sciences, Inc.

17. Funding To Date • National Institutes of Health • National Cancer Institute • Susan G. Komen For The Cure • California Breast Cancer Initiative • US Department of Defense • US Federal Grant • Private Investors Applied Integrin Sciences, Inc.

18. Clinical/Regulatory Strategy • Approve VCN as Anti-Angiogenic Therapy To: • Reduce Tumor Progression • Improve Safety • Improve Survival • Improve Efficacy • As Late Stage Therapy • 1st Indication: Triple Negative BrCA (Orphan Status) • Advance Multiple Indications • Collect/Establish Anti-Metastatic Data & Indication • Establish First-Line Solid Tumor Therapy Indication Applied Integrin Sciences, Inc.

19. Clinical Development Timeline VCN Protein Manufacture/CMC: $2.0 M PK/Tox: $1.2 M IND: $200 K Events & Milestones PI: $1.8 M Phase II Trials: $12 M Regulatory; Business Development; IP; General Corporate: $4.8 M Partner VCN 0 6 12 18 24 Yr 3 Yr 4 Months Applied Integrin Sciences, Inc.

20. Futures: Product Opportunities • Lead Candidate • 2nd Candidate • Scope of VCN and ADM01 • Platform Technology • Scope of ADM Platform VCN ADM01 Rx, Imaging, Dx 23 ADAM-Derived Disintegrins Multiple Disease States & Indications Therapeutics, Diagnostics, Imaging, Anti-Bacterials, Anti-Virals Applied Integrin Sciences, Inc.

21. Intellectual Property • Current Patent Protection: • Nine Issued Patents • Additional Patents and IP In Development • August 30, 2011: • Patent Issued for Combination Therapy • Docetaxel & VCN • February 7, 2012: • Patent Issued For Protein Expression • Substantial IP Portfolio Upside Opportunity Applied Integrin Sciences, Inc.

22. Industry Experienced Team • Thomas C. Boone, Chief Scientific Officer • Former Vice President Amgen Protein Sciences, Neupogen • Thomas C. Chen, M.D., Ph.D., Chief Medical Officer • USC Surgical Neuro-Oncology, Prof. Neurosurgery & Pathology • Dr. Debu Tripathy, M.D., Ph.D., Clinical Advisor • Director Women’s Health, USC; UCSF; Leading BrCA Oncologist • Diane L. Balma, J.D., Director • EVP Public Policy, Susan G. Komen, ExecDir Stand Up To Cancer • Alfred E. Mann Institute for Biomedical Engineering • Jon Lasch, Ph.D., Executive Director • Douglas C. Lane, Chief Executive Officer • Former SmithKline Beecham Pharma R&D; Prior CEO Experience Applied Integrin Sciences, Inc.

23. ScienceTeam-Company Founders • Francis S. Markland, Jr., Ph.D. • USC Keck Medical School Professor: Disintegrin Discovery Scientist and Expert • Stephen Swenson, Ph.D. • USC Keck Medical School Associate Professor • Radu Minea, M.D. • Discovered ADM01 and ADAM Derived Disintegrin Platform Applied Integrin Sciences, Inc.

24. 12 Month Company Developments • Improve Recombinant Expression (Non-Ampicillin) • Refine Protein Extraction, Purification (Commercial) • In Vivo Combination Therapy Results (Unpublished) • Additional Patents: • Combination Therapy: VCN & Docetaxel – August 2011 • Novel Protein Expression Methods – February 2012 • Personnel: • Tom Boone, Chief Scientific Officer • Dr. Debu Tripathy, M.D., Clinical Oncologist Advisor/PI • Forbes Article: May 22, 2012 Applied Integrin Sciences, Inc.

25. Summary • Novel, High Value Assets • Comparable To Leading Cancer Drug • Efficacy In Multiple Cancer Types • Disruptive To Industry And Competitive • Anti-Angiogenic and Anti-Metastatic Effect • Profile of Improved Safety and Efficacy from Novel MOA • Multiple ‘Shots-On-Goal’ • Two Lead Candidates Plus Prolific Platform • Industry Experienced Team That Can Execute Applied Integrin Sciences, Inc.

26. Thank You Discussion & Questions Applied Integrin Sciences, Inc. For Additional Information Please Contact: Douglas C. Lane, Chief Executive Officer Applied Integrin Sciences, Inc. 10940 Wilshire Blvd., Suite 1600 Los Angeles, CA 90024 Office: 310-443-4254 Direct: 310-457-0982 Cell: 310-490-0567 Email: dclane@integrins.com Web: www.integrins.com Applied Integrin Sciences, Inc.